Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.

doi:10.1038/s41467-021-25769-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.

Nature communications - 21 Sept 2021

Keenan Tanya E, Guerriero Jennifer L, Barroso-Sousa Romualdo, Li Tianyu, O'Meara Tess, Giobbie-Hurder Anita, Tayob Nabihah, Hu Jiani, Severgnini Mariano, Agudo Judith, Vaz-Luis Ines, Anderson Leilani, Attaya Victoria, Park Jihye, Conway Jake, He Meng Xiao, Reardon Brendan, Shannon Erin, Wulf Gerburg, Spring Laura M, Jeselsohn Rinath, Krop Ian, Lin Nancy U, Partridge Ann, Winer Eric P, Mittendorf Elizabeth A, Liu David, Van Allen Eliezer M, Tolaney Sara M

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have minimal therapeutic effect in hormone receptor-positive (HR+ ) breast cancer. We present final overall survival (OS) results (n = 88) from a randomized phase 2 trial of eribulin ± pembrolizumab for patients with metastatic HR+ breast cancer, computationally dissect genomic and/or transcriptomic data from pre-treatment tumors (n = 52) for molecular associations with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen Presentation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Estrogens

Share to Furans

Share to Immune Checkpoint Inhibitors

Share to Ketones

Share to Lymphocytes, Tumor-Infiltrating

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 34548479
DOI: 10.1038/s41467-021-25769-z
PMCID: PMC8455578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.PMID 34548479Read ↗

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Semantic proximity Read ↗

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read ↗

Multiomic dissection of HR <sup>+</sup> /HER2 <sup>−</sup> invasive lobular breast carcinoma reveals mobilized yet dysfunctional anti-tumor immunity shaped by tumor-stroma crosstalk and impaired antigen presentationSemantic proximity Read ↗

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity Read ↗

An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancerSemantic proximity Read ↗

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment ApproachSemantic proximity Read ↗

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer SubtypesSemantic proximity Read ↗

Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancerSemantic proximity Read ↗

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures.Semantic proximity Read ↗

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read ↗

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemo-immunotherapy in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.